Puma Biotechnology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter net product revenue of $54.1 million and nine-month income from operations of $9.031 million.

Key Highlights

  • Q3 2026 net product revenue: $54,112 thousand, up from $51,902 thousand in Q3 2025, according to the filing.
  • Nine-month total revenue: $156,372 thousand for the nine months ended September 30, 2026, compared to $152,918 thousand for the same period in 2025.
  • Accumulated deficit reduced: The filing reported an accumulated deficit of $1,273,383 thousand at September 30, 2026, down from $1,283,775 thousand at December 31, 2025.
  • Total stockholders' equity increased: $146,614 thousand at September 30, 2026, compared to $130,340 thousand at December 31, 2025.
  • Cash and cash equivalents: $41,548 thousand at September 30, 2026, versus $29,635 thousand at December 31, 2025.
  • Long-term debt retired: The current portion of long-term debt was $0 at September 30, 2026, down from $22,523 thousand at December 31, 2025.
  • Shares outstanding: 51,688,943 shares as of September 30, 2026, per the balance sheet, with 51,698,356 shares reported as of November 2, 2026.

Puma Biotechnology's Financial Position and Operating Results for Q3 2026

Puma Biotechnology, Inc. (NASDAQ:PBYI) reported total revenue of $55,056 thousand for the three months ended September 30, 2026, compared to $54,475 thousand for the same quarter in 2025, according to the filing. Net product revenue, which the company generates primarily from NERLYNX (neratinib) tablets, was $54,112 thousand in Q3 2026 versus $51,902 thousand in Q3 2025. Royalty revenue for the quarter was $944 thousand, down from $2,573 thousand a year earlier.

Total operating costs and expenses for Q3 2026 were $49,782 thousand, compared to $44,902 thousand in Q3 2025. Research and development expenses increased to $18,283 thousand from $15,912 thousand year-over-year for the quarter, while selling, general and administrative expenses declined to $16,301 thousand from $16,817 thousand. Income from operations for the third quarter was $5,274 thousand, compared to $9,573 thousand in Q3 2025. For the nine months ended September 30, 2026, income from operations was $9,031 thousand versus the prior-year comparable figure in the filing.

On the balance sheet, total assets were $202,768 thousand at September 30, 2026, down from $216,302 thousand at December 31, 2025. Total liabilities decreased to $56,154 thousand from $85,962 thousand over the same period, a reduction the filing attributes in part to the elimination of the current portion of long-term debt, which stood at $22,523 thousand at year-end 2025 and zero at the end of the third quarter. Marketable securities were $67,027 thousand at September 30, 2026. The filing also notes a material weakness remediation effort as one of the forward-looking topics the company has addressed in its cautionary disclosures; all forward-looking statements in the filing are the company's own and subject to its stated cautionary language.

What Was Disclosed

Puma Biotechnology filed its quarterly report covering the period ended September 30, 2026, disclosing unaudited condensed consolidated financial statements, management's discussion and analysis, and other required items including legal proceedings and risk factors.